Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: Intermediates and methods of their use in the synthesis of anslogs of halichondrin B are provided.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.

Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).

Abstract: The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E6070.

Abstract: Extracting natural occurring volatile minerals using external and internal electromagnetic fields. FIG. 1 & FIG. 2: By passing the volatile solutions (23) and feed materials (126) through a closed container (14)(128) in the proximity of a electromagnetic field or corona. The electromagnetic field consists of electrodes placed on appropriate material either on the inside or the outside of the metal container (14)(128) and energized. Volatile gases are sent to recovery. FIG. 3: Feed materials (212) can be fed on a enclosed conveyer (214) beneath a wrapped rod tube electrode (218) suspended above and lengthwise of the belt. Volatile gases are drawn off the top of the metal container (128) and sent to recovery. FIG. 4: An electromagnetic probe (304) is inserted into a bore hole (302). When energized volatile gases are trapped in a cone shaped cover (306) or other appropriate containment covering the top of the bore hole (302) and sent to recovery.

Abstract: This is a process of trapping natural occurring volatile gases carrying precious and other minerals in a semi-stable form. Gases trapped and carried through a container 318 apparatus to the catalytic reactor container 410 where volatile minerals are contained on an appropriate configuration of collecting media 434. A positive electrode 460 from a electrical source 430 is wrapped on the catalytic reactor container 410 in a appropriate configuration to induce a electromagnetic field. The positive electrode 460 from the catalytic reactor container is controlled by a rheostat 470. From the rheostat 470 to the electrical device causing the current draw 425. When the rheostat 470 is energized on the catalytic reactor container 410, electromagnet fields of varying intensity controlled by the rheostat are formed. Precious metals can be re-volatilized either singularly or in groups and drawn into the recovery circuit. Leaving most of the volatile elements still in the collecting media 434.

Abstract: A process to liberate volatile precious metals, and other minerals using air injection (FIG. 1). Volatile precious metals contained in aqueous or chemical solution(s), or slurries, including feed material(s) can be successfully extracted at a low cost using air/gas injection. It can be run continuously through the extraction apparatus at a large volume (FIG. 1). Air/gas is injected into the aqueous or chemical solution or slurry (229) and agitated by the impeller (232) or by natural or mechanical means to break down the air to small bubbles and disburse them throughout the aqueous or chemical solution, or slurries (229). The bubbles ascend and rise to the top of the tank or container (238) where the pregnant gasses are drawn off into the gas scrubbing tower (256). Or as in the feed material process, referring now to (FIG. 2), air is circulating up or through the feed material of a predetermined size and moisture content, in a enclosed tank or container (307).

Abstract: A microwave surface acoustic wave resonator stabilized oscillator includes an amplifier having an input terminal and an output terminal and a feedback circuit disposed around said amplifier for providing a closed loop about said amplifier having an integral multiple of 2.pi. radians of phase shift and excess small signal gain at a frequency f.sub.o. The SAW resonator is disposed in the feedback means and is selected to operate in a fundamental mode of operation and provides a resonant circuit having a resonant frequency f.sub.o. The feedback circuit around the amplifier causes the loop to oscillate at a frequency at which the phase shift is an integral multiple of 2.pi. radians and which has excess small signal gain. As the circuit starts to oscillate, the overall gain in the loop is compressed and the loop amplifier is forced to operate in a non-linear region.

Abstract: A surface acoustic wave (SAW) device provides a phase shift and a first predetermined phase shift variation as a function of temperature. A passive network including a passive, reactive component is thermally and electrically coupled to the SAW device. An electrical characteristic of the component has a predetermined variation as a function of the temperature of the reactive component which provides the network with a second, predetermined phase variation as a function of temperature to compensate for the first predetermined phase variation as a function of temperature provided from the surface acoustic wave device. With this arrangement, the phase shift provided from the surface acoustic wave device is substantially invariant with temperature.